In neuroscience swap, Amgen buys into Novartis’ BACE drug program for Alzheimer’s

Amgen is buying into Novartis’ early-stage BACE program for Alzheimer’s, paying an unspecified upfront and milestones in exchange for a cut of the program, which looks to slash the production of a key toxic protein widely viewed as a prime suspect in the development of the memory-wasting ailment. The risk-sharing deal focuses closely on Novartis’ Phase I/IIa BACE inhibitor (CNP520), which will be the lead molecule in a collaboration that will also pool the two giants’ preclinical BACE drugs. Amgen is willing to cover the lion’s share of the research costs for an initial period in the quid pro quo partnership, followed by a 50/50 split. And the big biotech says it was encouraged to enter into the collaboration after the BACE target’s genetic authenticity was confirmed by Amgen subsidiary…


Link to Full Article: In neuroscience swap, Amgen buys into Novartis’ BACE drug program for Alzheimer’s